HRP20250920T1 - Miševi koji imaju modificirani lambda laki lanac imunoglobulina i njihove upotrebe - Google Patents

Miševi koji imaju modificirani lambda laki lanac imunoglobulina i njihove upotrebe

Info

Publication number
HRP20250920T1
HRP20250920T1 HRP20250920TT HRP20250920T HRP20250920T1 HR P20250920 T1 HRP20250920 T1 HR P20250920T1 HR P20250920T T HRP20250920T T HR P20250920TT HR P20250920 T HRP20250920 T HR P20250920T HR P20250920 T1 HRP20250920 T1 HR P20250920T1
Authority
HR
Croatia
Prior art keywords
human
gene
segments
mouse
light chain
Prior art date
Application number
HRP20250920TT
Other languages
English (en)
Croatian (hr)
Inventor
Andrew J Murphy
Lynn Macdonald
Chunguang GUO
John Mcwhirter
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of HRP20250920T1 publication Critical patent/HRP20250920T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1264—DNA nucleotidylexotransferase (2.7.7.31), i.e. terminal nucleotidyl transferase
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Environmental Sciences (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HRP20250920TT 2017-12-05 2018-12-04 Miševi koji imaju modificirani lambda laki lanac imunoglobulina i njihove upotrebe HRP20250920T1 (hr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762594946P 2017-12-05 2017-12-05
US201762594944P 2017-12-05 2017-12-05
US201762609251P 2017-12-21 2017-12-21
US201762609241P 2017-12-21 2017-12-21
EP22188627.8A EP4140297B1 (en) 2017-12-05 2018-12-04 Mice having an engineered immunoglobulin lambda light chain and uses thereof

Publications (1)

Publication Number Publication Date
HRP20250920T1 true HRP20250920T1 (hr) 2025-09-26

Family

ID=64734263

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20250920TT HRP20250920T1 (hr) 2017-12-05 2018-12-04 Miševi koji imaju modificirani lambda laki lanac imunoglobulina i njihove upotrebe
HRP20221459TT HRP20221459T1 (hr) 2017-12-05 2018-12-04 Miševi koji imaju modificirani lambda laki lanac imunoglobulina i njihove upotrebe

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20221459TT HRP20221459T1 (hr) 2017-12-05 2018-12-04 Miševi koji imaju modificirani lambda laki lanac imunoglobulina i njihove upotrebe

Country Status (24)

Country Link
US (4) US11051498B2 (https=)
EP (3) EP4140297B1 (https=)
JP (3) JP7430636B2 (https=)
KR (2) KR102760506B1 (https=)
CN (2) CN111432635B (https=)
AU (2) AU2018381316B2 (https=)
BR (1) BR112020011184A2 (https=)
CA (1) CA3084049A1 (https=)
DK (2) DK4140297T3 (https=)
ES (2) ES3035461T3 (https=)
FI (1) FI4140297T3 (https=)
HR (2) HRP20250920T1 (https=)
HU (2) HUE060608T2 (https=)
IL (2) IL318197A (https=)
LT (2) LT4140297T (https=)
MX (2) MX2020005830A (https=)
PL (2) PL4140297T3 (https=)
PT (2) PT4140297T (https=)
RS (2) RS63772B1 (https=)
SG (1) SG11202003044SA (https=)
SI (2) SI3720279T1 (https=)
SM (2) SMT202500277T1 (https=)
TW (2) TWI827567B (https=)
WO (1) WO2019113065A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6482757B2 (ja) 2010-07-26 2019-03-13 トリアンニ インコーポレイテッドＴｒｉａｎｎｉ，Ｉｎｃ． トランスジェニック動物および使用方法
US10662256B2 (en) 2010-07-26 2020-05-26 Trianni, Inc. Transgenic mammals and methods of use thereof
PL2958937T3 (pl) 2013-02-22 2019-01-31 Regeneron Pharmaceuticals, Inc. Myszy ekspresjonujące humanizowany główny układ zgodności tkankowej
EP3384030A4 (en) 2015-12-03 2019-07-03 Trianni, Inc. IMPROVED IMMUNOGLULINIVITY
DK4140297T3 (da) 2017-12-05 2025-06-23 Regeneron Pharma Mus med en konstrueret immunglobulin-lambda-letkæde og anvendelser deraf
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
JP2022520819A (ja) 2019-02-22 2022-04-01 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 遺伝子改変ナトリウムチャネルを有する齧歯類およびその使用方法
WO2021003152A1 (en) * 2019-07-01 2021-01-07 Trianni, Inc. Transgenic mammals and methods of use thereof
CA3144956A1 (en) * 2019-07-01 2021-01-07 Trianni, Inc. Transgenic mammals and methods of use
CA3187680A1 (en) 2020-09-11 2022-03-17 Yashu Liu Identification and production of antigen-specific antibodies
WO2022132943A1 (en) 2020-12-16 2022-06-23 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
TW202242114A (zh) 2020-12-23 2022-11-01 美商再生元醫藥公司 用於獲得結合至跨膜蛋白之抗體以及抗體生成細胞的方法
CA3165366A1 (en) 2020-12-23 2022-06-30 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding anchor modified antibodies and uses thereof
CN114763558B (zh) * 2021-01-14 2024-02-20 上海泰槿生物技术有限公司 重组基因组、非人哺乳动物细胞及其产生方法和用途
AU2022249328A1 (en) * 2021-03-31 2023-09-21 Regeneron Pharmaceuticals, Inc. Genetically modified mice comprising humanized cellular immune system components with improved diversity of tcrβ repertoire
CN121065267A (zh) * 2024-06-04 2025-12-05 赛业（苏州）生物科技有限公司 用于制备四元固定轻链的基因修饰的啮齿动物及其制备方法
EP4671705A1 (de) 2024-06-25 2025-12-31 Harro Höfliger Verpackungsmaschinen GmbH Vorrichtung und verfahren zum prüfen des sprühstrahls einer baugruppe für sprühapplikatoren
WO2026030428A2 (en) 2024-08-01 2026-02-05 Regeneron Pharmaceuticals, Inc. Prostate-specific antigen peptides and uses thereof
WO2026035843A2 (en) 2024-08-06 2026-02-12 Regeneron Pharmaceuticals, Inc. Non-human animals having modified immunoglobulin heavy chain constant region locus and uses thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
AU669124B2 (en) * 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
US5670356A (en) 1994-12-12 1997-09-23 Promega Corporation Modified luciferase
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
EP1500329B1 (en) * 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
GB9823930D0 (en) 1998-11-03 1998-12-30 Babraham Inst Murine expression of human ig\ locus
EA013564B1 (ru) * 2000-08-03 2010-06-30 Терапеутик Хьюман Поликлоналз Инк. Гуманизированный иммуноглобулин и содержащая его фармацевтическая композиция
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) * 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7435871B2 (en) 2001-11-30 2008-10-14 Amgen Fremont Inc. Transgenic animals bearing human Igλ light chain genes
ES2398076T3 (es) 2006-06-02 2013-03-13 Regeneron Pharmaceuticals, Inc. Anticuerpos de alta afinidad contra el receptor de IL-6 humano
CA2696934A1 (en) * 2007-09-12 2010-02-16 Probiodrug Ag Transgenic mice
PL3456190T3 (pl) * 2008-06-27 2022-06-06 Merus N.V. Wytwarzające przeciwciała transgeniczne zwierzę z gatunku myszy
EP2346994B1 (en) 2008-09-30 2022-02-16 Ablexis, LLC Knock-in mice for the production of chimeric antibodies
BR112012000536A2 (pt) 2009-07-08 2020-08-11 Kymab Limited métodos para produção de anticorpo ou cadeia leve ou pesada de anticorpo específico para um antígeno desejado, para produção de anticorpo ou cadeia de anticorpo e seu uso, composição farmacêutica e derivado de anticorpo quimérico
US9445581B2 (en) * 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
RU2425880C2 (ru) 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
US9012717B2 (en) 2010-06-22 2015-04-21 Regeneron Pharmaceuticals, Inc. Human lambda light chain mice
RU2722373C2 (ru) 2011-02-25 2020-05-29 Редженерон Фармасьютикалс, Инк. Мыши adam6
KR20160098514A (ko) 2011-10-17 2016-08-18 리제너론 파아마슈티컬스, 인크. 제한된 면역글로불린 중쇄 마우스
US9253965B2 (en) * 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
RU2664181C2 (ru) * 2011-12-20 2018-08-15 Регенерон Фармасьютикалз, Инк. Мыши с гуманизированной легкой цепью
RS62023B1 (sr) 2012-02-01 2021-07-30 Regeneron Pharma Humanizovani glodari koji eksprimiraju teške lance koji sadrže vl domene
PT3597037T (pt) * 2012-06-12 2021-06-01 Regeneron Pharma Animais não humanos humanizados com lócus de cadeia pesada de imunoglobulina restrito
MX2015010841A (es) 2013-02-20 2016-05-09 Regeneron Pharma Modificacion genetica de ratas.
SI2986729T1 (sl) 2013-04-16 2019-02-28 Regeneron Pharmaceuticals, Inc. Ciljana sprememba genoma podgane
DE112014004537T5 (de) * 2013-10-01 2016-07-21 Kymab Limited Tiermodelle und therapeutische Moleküle
HUE049405T2 (hu) 2014-06-23 2020-09-28 Regeneron Pharma Nukleáz-közvetített DNS-összeállítás
ES2731437T3 (es) 2014-11-21 2019-11-15 Regeneron Pharma Métodos y composiciones para la modificación genética dirigida mediante el uso de pares de ARN guías
KR102530821B1 (ko) 2014-12-19 2023-05-10 리제너론 파마슈티칼스 인코포레이티드 단일 단계 다중 표적화를 통한 표적화된 유전자 변형을 위한 방법 및 조성물
HUE061619T2 (hu) 2016-06-03 2023-07-28 Regeneron Pharma Exogén terminális dezoxinukleotid-transzferázt expresszáló rágcsálók
GB201710984D0 (en) * 2017-07-07 2017-08-23 Kymab Ltd Cells, vertebrates, populations & methods
DK4140297T3 (da) 2017-12-05 2025-06-23 Regeneron Pharma Mus med en konstrueret immunglobulin-lambda-letkæde og anvendelser deraf

Also Published As

Publication number Publication date
LT3720279T (lt) 2022-10-25
RU2020118699A (ru) 2022-01-10
EP4596688A3 (en) 2025-11-12
ES2928995T3 (es) 2022-11-24
EP4140297A1 (en) 2023-03-01
US20210345591A1 (en) 2021-11-11
SMT202200448T1 (it) 2023-01-13
HRP20221459T1 (hr) 2023-01-20
JP2026016575A (ja) 2026-02-03
CA3084049A1 (en) 2019-06-13
IL318197A (en) 2025-03-01
KR20200093570A (ko) 2020-08-05
KR20250022220A (ko) 2025-02-14
IL274797B1 (en) 2025-02-01
FI4140297T3 (fi) 2025-07-10
SI3720279T1 (sl) 2022-11-30
TWI827567B (zh) 2024-01-01
SI4140297T1 (sl) 2025-08-29
JP2021505141A (ja) 2021-02-18
ES3035461T3 (en) 2025-09-03
EP3720279B1 (en) 2022-09-21
HUE071852T2 (hu) 2025-09-28
RS63772B1 (sr) 2022-12-30
KR102760506B1 (ko) 2025-02-04
US20260020545A1 (en) 2026-01-22
JP7430636B2 (ja) 2024-02-13
BR112020011184A2 (pt) 2020-11-17
CN116058333A (zh) 2023-05-05
JP7765514B2 (ja) 2025-11-06
JP2024036440A (ja) 2024-03-15
LT4140297T (lt) 2025-07-25
TW201938019A (zh) 2019-10-01
EP4140297B1 (en) 2025-05-21
PL3720279T3 (pl) 2023-01-16
SG11202003044SA (en) 2020-04-29
SMT202500277T1 (it) 2025-09-12
IL274797B2 (en) 2025-06-01
IL274797A (en) 2020-07-30
MX2024004496A (es) 2024-05-08
CN111432635B (zh) 2022-10-21
US11051498B2 (en) 2021-07-06
CN111432635A (zh) 2020-07-17
EP4596688A2 (en) 2025-08-06
RU2020118699A3 (https=) 2022-04-07
DK3720279T3 (da) 2022-10-24
PT4140297T (pt) 2025-07-09
AU2018381316B2 (en) 2025-06-26
EP3720279A1 (en) 2020-10-14
MX2020005830A (es) 2020-08-20
WO2019113065A1 (en) 2019-06-13
DK4140297T3 (da) 2025-06-23
HUE060608T2 (hu) 2023-03-28
US20210292439A1 (en) 2021-09-23
TW202438676A (zh) 2024-10-01
PT3720279T (pt) 2022-10-06
US12356967B2 (en) 2025-07-15
PL4140297T3 (pl) 2025-08-25
US20190223418A1 (en) 2019-07-25
AU2018381316A1 (en) 2020-04-23
RS67058B1 (sr) 2025-08-29
AU2025204547A1 (en) 2025-07-10

Similar Documents

Publication Publication Date Title
HRP20250920T1 (hr) Miševi koji imaju modificirani lambda laki lanac imunoglobulina i njihove upotrebe
HRP20220253T1 (hr) Miševi s ograničenim teškim lancem imunoglobulina
HRP20191191T1 (hr) Miš sa zajedničkim lakim lancem
NZ743520A (en) Humanized universal light chain mice
JP5756802B2 (ja) 最小ｃｄｒを有する抗体を産生するトランスジェニック動物
NZ730271A (en) Non-human animals expressing ph-sensitive immunoglobulin sequences
EP1664343B1 (en) Methods and compositions for generation of germline human antibody genes
AU2024200582A1 (en) Non-human animals having an engineered immunoglobulin lambda light chain locus
HRP20200093T1 (hr) Humanizirane neljudske životinje s ograničenim lokusima imunoglobulinskog teškog lanca
CA2899740A1 (en) B cell lineage based immunogen design with humanized animals
US20250388651A1 (en) Transgenic chicken that makes antibodies with long cdr-h3s stabilized by multiple disulfide bridges and diversified by gene conversion
NZ763183B2 (en) Non-human animals having an engineered immunoglobulin lambda light chain and uses thereof
NZ763183A (en) Non-human animals having an engineered immunoglobulin lambda light chain and uses thereof
CA3102122A1 (en) Transgenic chicken with functionally deleted igy ch1 coding sequence
US12102070B2 (en) Camelization of a human variable domain by gene conversion
AU2019284252B2 (en) Production of antibodies by modification of an autonomous heavy chain variable domain by gene conversion
MC et al. Novato, CA 94949 (US)
NZ753456B2 (en) Non-human animals having an engineered immunoglobulin lambda light chain locus